Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Sonoma Pharmaceuticals Inc
Total Receivables
Sonoma Pharmaceuticals Inc
Total Receivables Peer Comparison
Competitive Total Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
Total Receivables
$2.9m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
1%
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Receivables
$14.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Receivables
$14.1B
|
CAGR 3-Years
18%
|
CAGR 5-Years
20%
|
CAGR 10-Years
17%
|
|
Pfizer Inc
NYSE:PFE
|
Total Receivables
$15.2B
|
CAGR 3-Years
16%
|
CAGR 5-Years
10%
|
CAGR 10-Years
5%
|
|
Merck & Co Inc
NYSE:MRK
|
Total Receivables
$12.1B
|
CAGR 3-Years
14%
|
CAGR 5-Years
10%
|
CAGR 10-Years
5%
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Receivables
$10B
|
CAGR 3-Years
15%
|
CAGR 5-Years
14%
|
CAGR 10-Years
10%
|
See Also
What is Sonoma Pharmaceuticals Inc's Total Receivables?
Total Receivables
2.9m
USD
Based on the financial report for Dec 31, 2023, Sonoma Pharmaceuticals Inc's Total Receivables amounts to 2.9m USD.
What is Sonoma Pharmaceuticals Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
1%
Over the last year, the Total Receivables growth was 25%. The average annual Total Receivables growth rates for Sonoma Pharmaceuticals Inc have been -13% over the past three years , -2% over the past five years , and 1% over the past ten years .